在Côte科特迪瓦结直肠癌患者中首次检测到KRAS突变

Tata G. S. Coulibaly, Valérie M. Gbonon, Akandji Osseni, F. B. Diplo, D. N. Coulibaly, A. Sylla, S. Ngazoa, Moktar Toure, M. Dosso
{"title":"在Côte科特迪瓦结直肠癌患者中首次检测到KRAS突变","authors":"Tata G. S. Coulibaly, Valérie M. Gbonon, Akandji Osseni, F. B. Diplo, D. N. Coulibaly, A. Sylla, S. Ngazoa, Moktar Toure, M. Dosso","doi":"10.24018/ejbiomed.2022.1.5.30","DOIUrl":null,"url":null,"abstract":"Advances in molecular biology tools have made it possible to make progress in terms of therapeutics by acting specifically on the molecular mechanisms involved in the virulence of pathogens or in the development of the disease. In the case of cancer, new therapeutics have been developed thanks to these advances. This is called targeted therapy. Targeted therapy molecules specifically act as a molecule, or a molecular pathway involved in the development of the tumor. The use of targeted therapy drugs therefore requires molecular characterization of tumors. In developing countries, the reference tool is high-throughput sequencing, but due to the high cost, this strategy remains inaccessible for the majority of African populations. It is remains necessary to implement alternative molecular diagnostic tools in order to reduce the disparities currently observed in access to cancer care. The High-Resolution Melting analysis (HRM) method is based on real-time PCR and is described as a simple, rapid and specific method for the detection of somatic mutations predictive of anti-tumor therapeutic response. We demonstrated in this study that this method could be implemented in a lower middle-income country like Côte d’Ivoire, and we used it to detect KRAS mutations in colorectal cancer patients for the first time in Cote d’Ivoire.","PeriodicalId":72970,"journal":{"name":"European journal of biomedical research","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"First Detection of KRAS Mutation in Colorectal Cancer Patients in Côte d’Ivoire\",\"authors\":\"Tata G. S. Coulibaly, Valérie M. Gbonon, Akandji Osseni, F. B. Diplo, D. N. Coulibaly, A. Sylla, S. Ngazoa, Moktar Toure, M. Dosso\",\"doi\":\"10.24018/ejbiomed.2022.1.5.30\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advances in molecular biology tools have made it possible to make progress in terms of therapeutics by acting specifically on the molecular mechanisms involved in the virulence of pathogens or in the development of the disease. In the case of cancer, new therapeutics have been developed thanks to these advances. This is called targeted therapy. Targeted therapy molecules specifically act as a molecule, or a molecular pathway involved in the development of the tumor. The use of targeted therapy drugs therefore requires molecular characterization of tumors. In developing countries, the reference tool is high-throughput sequencing, but due to the high cost, this strategy remains inaccessible for the majority of African populations. It is remains necessary to implement alternative molecular diagnostic tools in order to reduce the disparities currently observed in access to cancer care. The High-Resolution Melting analysis (HRM) method is based on real-time PCR and is described as a simple, rapid and specific method for the detection of somatic mutations predictive of anti-tumor therapeutic response. We demonstrated in this study that this method could be implemented in a lower middle-income country like Côte d’Ivoire, and we used it to detect KRAS mutations in colorectal cancer patients for the first time in Cote d’Ivoire.\",\"PeriodicalId\":72970,\"journal\":{\"name\":\"European journal of biomedical research\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of biomedical research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24018/ejbiomed.2022.1.5.30\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24018/ejbiomed.2022.1.5.30","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

分子生物学工具的进步使得在治疗方法方面取得进展成为可能,方法是具体作用于病原体毒性或疾病发展过程中涉及的分子机制。就癌症而言,由于这些进步,新的治疗方法已经开发出来。这被称为靶向治疗。靶向治疗分子特异性地作为一个分子,或分子途径参与肿瘤的发展。因此,使用靶向治疗药物需要对肿瘤进行分子表征。在发展中国家,参考工具是高通量测序,但由于成本高昂,大多数非洲人口仍然无法获得这一策略。仍然有必要实施替代分子诊断工具,以减少目前在获得癌症治疗方面观察到的差距。高分辨率熔化分析(HRM)方法基于实时PCR,被描述为一种简单、快速和特异性的方法,用于检测预测抗肿瘤治疗反应的体细胞突变。在这项研究中,我们证明了这种方法可以在像Côte科特迪瓦这样的中低收入国家实施,并且我们首次在科特迪瓦使用它来检测结肠直肠癌患者的KRAS突变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
First Detection of KRAS Mutation in Colorectal Cancer Patients in Côte d’Ivoire
Advances in molecular biology tools have made it possible to make progress in terms of therapeutics by acting specifically on the molecular mechanisms involved in the virulence of pathogens or in the development of the disease. In the case of cancer, new therapeutics have been developed thanks to these advances. This is called targeted therapy. Targeted therapy molecules specifically act as a molecule, or a molecular pathway involved in the development of the tumor. The use of targeted therapy drugs therefore requires molecular characterization of tumors. In developing countries, the reference tool is high-throughput sequencing, but due to the high cost, this strategy remains inaccessible for the majority of African populations. It is remains necessary to implement alternative molecular diagnostic tools in order to reduce the disparities currently observed in access to cancer care. The High-Resolution Melting analysis (HRM) method is based on real-time PCR and is described as a simple, rapid and specific method for the detection of somatic mutations predictive of anti-tumor therapeutic response. We demonstrated in this study that this method could be implemented in a lower middle-income country like Côte d’Ivoire, and we used it to detect KRAS mutations in colorectal cancer patients for the first time in Cote d’Ivoire.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Bioinformatics Techniques for Developing Molecular Detection Methods for the HIV-1 Gag Gene Cytomorphological Analysis of Liquid PRF Produced with DUO Fixed Angle Centrifuge (Process, France) Amplification of Sars-Cov2 Viral Markers in Côte d’Ivoire Letrozole and HFD_HG on Insulin and GDP Vaccination Rate for COVID-19 in a Primary Healthcare Center in Greece
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1